Are you de-escalating treatment for favorable risk Stage I-II DLBCL patients to 4 cycles of R- CHOP with 2 additional rituximab cycles?  

Have you changed your practice based off the FLYER trial presented at ASH 2018?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice